Genmab (GMAB)
(Delayed Data from NSDQ)
$24.12 USD
+0.29 (1.22%)
Updated Sep 26, 2024 04:00 PM ET
After-Market: $24.11 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum B VGM
Brokerage Reports
Genmab A/S Sponsored ADR [GMAB]
Reports for Purchase
Showing records 21 - 40 ( 122 total )
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
sBLA Submitted For RYBREVANT + Chemo in EGFR+ NSCLC Post-Tagrisso; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Multiple Datasets Expected at ASH; 3Q23 Financials; Modulating PT to $49
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
TIVDAK and RYBREVANT Both Shine at ESMO; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
3Q23 DARZALEX Sales Announced; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Epcoritamab Obtains Conditional European Marketing Approval; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
TIVDAK InnovaTV-301 Trial Meets Overall Survival Endpoint; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
TALVEY Granted Accelerated Approval by FDA; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
2Q23 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
DARZALEX 2Q23 Sales Announced; Guidance Raised; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Epcoritamab Relapsed/Refractory Follicular Lymphoma Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Epcoritamab Added to National Clinical Practice Guidelines; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Epcoritamab Clinical Program and Competitive Landscape Updates; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
NICE Recommends DARZALEX in 2L Multiple Myeloma; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Epcoritamab Receives Accelerated Approval; Raising PT to $51
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
1Q23 Financials; Multiple Datasets at ASCO and EHA; Raising PT to $47
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
DARZALEX 1Q23 Sales Announced; argenx SE Partnership; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
2022 Financials; Multiple Catalysts This Year; Modulating PT to $46
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Numerous Epcoritamab ASH Takeaways; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Epcoritamab Submitted to FDA; Scancell Collaboration Inked; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
DARZALEX 3Q22 Reported Sales In Line With Our Forecasts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R